Patents by Inventor CAI-YUE ZHU

CAI-YUE ZHU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-(3,4-dihydroxyphenyl)ethyl 3-hydroxybutanoate, composition, and method for improving function of aortic endothelial cell
    Patent number: 10947179
    Abstract: The disclosure relates to a compound, 2-(3,4-dihydroxyphenyl)ethyl 3-hydroxybutanoate, for improving aortic endothelial cell function and use thereof. The compound is capable of inhibiting inflammatory response of the human aortic endothelial cells caused by a saturated fatty acid, and preventing an occurrence and progression of atherosclerosis. The compound is capable of reducing human aortic endothelial inflammation caused by a saturated fatty acid, for example, reducing the mRNA levels of interleukin-6 (IL-6), and is capable of effectively protecting the function of mitochondria in human aortic endothelium from being damaged by a saturated fatty acid, for example, increasing the expression of mitochondrial complex I.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: March 16, 2021
    Assignee: XI'AN JIAOTONG UNIVERSITY
    Inventors: Jian-Kang Liu, Xu-Yun Liu, Ya-Chong Hu, Lin Zhao, Yong-Yao Wang, Cai-Yue Zhu, Zhen Wang, Jing Lou, Qing-Qing Ma, Yu-Xia Zhang, Qing-Lin Jiang, Xiao-Hong Xu, Ting-Hua Zhang, Jian-Gang Long
  • 2-(3,4-DIHYDROXYPHENYL)ETHYL 3-HYDROXYBUTANOATE, COMPOSITION, AND METHOD FOR IMPROVING FUNCTION OF AORTIC ENDOTHELIAL CELL
    Publication number: 20210047262
    Abstract: The disclosure relates to a compound, 2-(3,4-dihydroxyphenyl)ethyl 3-hydroxybutanoate, for improving aortic endothelial cell function and use thereof. The compound is capable of inhibiting inflammatory response of the human aortic endothelial cells caused by a saturated fatty acid, and preventing an occurrence and progression of atherosclerosis. The compound is capable of reducing human aortic endothelial inflammation caused by a saturated fatty acid, for example, reducing the mRNA levels of interleukin-6 (IL-6), and is capable of effectively protecting the function of mitochondria in human aortic endothelium from being damaged by a saturated fatty acid, for example, increasing the expression of mitochondrial complex I.
    Type: Application
    Filed: September 26, 2019
    Publication date: February 18, 2021
    Applicant: XI'AN JIAOTONG UNIVERSITY
    Inventors: JIAN-KANG LIU, XU-YUN LIU, YA-CHONG HU, LIN ZHAO, YONG-YAO WANG, CAI-YUE ZHU, ZHEN WANG, JING LOU, QING-QING MA, YU-XIA ZHANG, QING-LIN JIANG, XIAO-HONG XU, TING-HUA ZHANG, JIAN-GANG LONG
  • USE OF HYDROXYTYROSOL ACETATE IN IMPROVING FUNCTION OF AORTIC ENDOTHELIAL CELL
    Publication number: 20200397718
    Abstract: The present disclosure discloses use of hydroxytyrosol acetate in preparation of a medicament for improving aortic endothelial cell function. The hydroxytyrosol acetate is capable of inhibiting an inflammation of aortic endothelial cells caused by a saturated fatty acid, reducing mRNA levels corresponding to matrix metalloproteinase-1 (MMP-1), intercellular adhesion molecule-1 (ICAM-1) and plasma plasminogen activator inhibitor-1 (PAI-1) in aortic endothelial cells and protecting mitochondria from being damaged by inflammation of aortic endothelial cells caused by a saturated fatty acid, preventing the occurrence and development of atherosclerosis by anti-inflammatory and protecting mitochondrial function.
    Type: Application
    Filed: June 10, 2020
    Publication date: December 24, 2020
    Inventors: JIAN-KANG LIU, XU-YUN LIU, XIAO-JIE WANG, YUE XIONG, LIN ZHAO, CAI-YUE ZHU